Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
Journal: Journal for immunotherapy of cancer
Published: August 03, 2026
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Journal: JAMA network open
Published: July 16, 2026
Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.
Journal: Frontiers in immunology
Published: April 06, 2026
Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 05, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.
Journal: NPJ precision oncology
Published: March 10, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Journal: Future oncology (London, England)
Published: March 04, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
Journal: The New England journal of medicine
Published: February 25, 2026
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: January 06, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.
Journal: NPJ precision oncology
Published: December 10, 2025
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
Journal: The oncologist
Published: September 30, 2025
PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation.
Journal: Future oncology (London, England)
Published: September 11, 2025
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
Journal: NPJ precision oncology
Published: September 09, 2025
Last Updated: 09/26/2026